Michael Castagna
Chief Executive Officer
Replay available
MannKind Corporation (MNKD) Q4 2025 Earnings Call
MannKind Corporation (NASDAQ: MNKD) Q4 2025 earnings conference call, held 2026-02-26. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Chris Prentice
Chief Financial Officer
Rowana Ruiz
Analyst, Learing Partners
Brandon Folks
Analyst, HC Wainwright & Co.
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Mannkind Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.941 good morning and welcome to the mankind corporation fourth quarter and full year 2025 00:00:04.941 -- 00:00:09.891 financial results earnings call as a reminder this call is being recorded on february 00:00:09.891 -- 00:00:11.695 26 2026 00:00:11.695 -- 00:00:16.044 and will be available for replay on the mankind corporation website shortly after this 00:00:16.044 -- 00:00:21.154 call and for approximately 90 days This call will contain forward-looking statements. 00:00:21.154 -- 00:00:25.301 Such forward-looking statements are subject to risks and uncertainties that may cause 00:00:25.301 -- 00:00:28.807 actual results to differ materially from these expectations. 00:00:28.807 -- 00:00:33.174 For further information on the company's risk factors, please see the Form 10-K for the 00:00:33.174 -- 00:00:36.560 annual period ended December 31, 2025, 00:00:36.560 -- 00:00:40.126 the earnings release, and the slides prepared for this presentation. 00:00:40.126 -- 00:00:45.032 Joining us today from Mankind are Chief Executive Officer Michael Castagna and Chief 00:00:45.032 -- 00:00:49.177 Financial Officer Chris Prentice. I'd now like to turn the conference over to Mr. 00:00:49.177 -- 00:00:51.580 Castagna. Please go ahead, sir. 00:00:51.580 -- 00:00:56.406 Thanks, operator. Good morning, everyone. Thank you for joining us for our Q4 and year-end 00:00:56.406 -- 00:01:02.731 2025 earnings call. Here's today's agenda, and I'll start with some opening remarks. 00:01:02.734 -- 00:01:06.879 I want to start by taking a step back and putting our relationship with United Therapeutics 00:01:06.879 -- 00:01:12.176 into context. Tyveso DPI has transformed both United Therapeutics and Mankind's 00:01:12.176 -- 00:01:16.440 future to fund our respec...